Core Viewpoint - Huaxi Biological has reported a seemingly contradictory financial performance for 2024, with total revenue of 5.371 billion yuan, a year-on-year decline of 11.61%, and a net profit of 174 million yuan, down 70.59%. However, the company increased its R&D investment by 4.46% to a record high of 466 million yuan, representing 8.68% of its revenue, positioning it among the leaders in A-shares [2][10]. Financial Performance - Total revenue for Huaxi Biological in 2024 was 5.371 billion yuan, a decrease of 11.61% year-on-year [2]. - Net profit fell to 174 million yuan, a significant drop of 70.59% [2]. - R&D investment reached 466 million yuan, marking a 4.46% increase and a historical high [2]. - The R&D expense ratio was 8.68%, placing the company at the forefront of the A-share market [2][10]. Business Strategy - The company aims to return to an entrepreneurial organization to awaken its innovative capabilities, as stated by Chairman Zhao Yan [2]. - Huaxi Biological's international revenue from raw materials reached 608 million yuan, a year-on-year increase of 17.65%, supported by FDA certification [5]. - The medical terminal business generated 1.44 billion yuan, a remarkable increase of 32.03%, becoming the largest revenue contributor [6]. - The functional skincare segment saw revenue decline by 31.62% to 2.569 billion yuan due to intensified market competition and channel adjustments [6]. R&D and Innovation - Huaxi Biological has established eight R&D platforms and holds 580 valid patents, with 392 applicable to its main business [7]. - The company is transitioning from a focus on hyaluronic acid to two foundational sciences: glycoscience and cell biology [9]. - The R&D team consists of 920 members, reflecting the company's commitment to long-term investment in innovation [10]. Market Position and Future Outlook - The FDA certification is expected to facilitate Huaxi Biological's expansion into high-end markets in Europe and the United States [4]. - The company is diversifying its business across four major fields: raw materials, medical devices, functional foods, and tissue engineering, creating a "cell-level anti-aging" ecosystem [9]. - Despite short-term profit pressures, Huaxi Biological announced a cash dividend of 52.62 million yuan, accounting for 30.19% of its net profit [9].

Group 1 - Norway celebrates its Constitution Day on May 17, marking the signing of the Norwegian Constitution in 1814, symbolizing independence and democratic spirit [1] - The 211th anniversary of Norway's Constitution Day was celebrated with events in Beijing and Shanghai, organized by the Norwegian Embassy in China, the Innovation Norway, and various enterprises [1][3] - NYO3, a core member of the Norwegian Health Products Group, focuses on innovative technology to redefine Omega-3 nutrition and promote the concept of "health and longevity" [1][3] Group 2 - Norway is known as a "long-lived country," with a long history of fish oil consumption, and Omega-3 is considered one of the secrets to longevity [3] - The Oslo Breakfast Program initiated by the Norwegian government in the early 20th century incorporated Omega-3 into children's dietary standards, establishing a foundation for national health [3] - NYO3 specializes in Antarctic krill oil, emphasizing the absorption benefits of its marine phospholipid structure, and has received multiple international quality certifications [3][5] Group 3 - Norway ranks high in gender equality, with female labor participation exceeding 80%, leading to a significant demand for anti-aging products among women [5] - NYO3 has partnered with NO-Age to launch the Ageless brand line, targeting early aging issues in women aged 25 and above, with innovative products that enhance absorption rates [5] - The Ageless Aurora Beauty Pills achieved top rankings in Tmall International's oral beauty category within the first month of launch and will be showcased at the 2025 Vitafoods Europe exhibition [5][6] Group 4 - To commemorate the 211th anniversary of Constitution Day, NYO3 launched a special campaign on Tmall International, offering consumers a chance to win health gifts, including a trip to Norway [6] - NYO3 aims to bridge cultural exchanges between China and Norway through its products, promoting a healthy Nordic lifestyle and enhancing global awareness of Norway [6]

真正优秀的成分，总会随着时间焕发新的生命力。 在护肤领域，透明质酸（ HA），也就是我们熟知的玻尿酸，堪称初代 "顶流巨星"。从保湿到抗皱，从修复到紧致，它的功效几乎覆盖了消费者对护肤 品的所有期待。然而，随着胜肽、烟酰胺等新兴成分的涌现，一时间，质疑声四起：曾经风靡护肤界的玻尿酸，如今是否还能保持它的优势？ 这种断层式领先表明，无论市场如何变化，透明质酸依然是品牌配方中的核心选择。 为什么透明质酸能够保持这样的地位？答案很简单 ——它不仅是一种经典成分，更是一种经过时间验证、安全可靠且功效显著的护肤原料。 透明质酸 的抗皱紧致 地位坚如磐石 数据不会撒谎。 根据中国香妆和用户说联合发布的《 2025原料成分趋势洞察榜单》，透明质酸稳坐"抗皱紧致"成分应用热度榜首。在2025年1-2月备 案的护肤品中，含有透明质酸的产品数量高达10562个，是第二名烟酰胺（5504个）的近两倍。 早期的透明质酸提取工艺复杂且成本高昂。 1949 年，Boas 从鸡冠中分离出透明质酸。提取 1g 透明质酸需要 200 公斤鸡冠（约 2 万只鸡），导致生 产成本极高，每公斤售价高达10万美元，被誉为"液体黄金"。 从 "液体黄金 ...

Core Viewpoint - GEMO Jinmo and LaClinic Montreux are collaborating to innovate in the field of cellular anti-aging technology, marking a significant advancement in high-end home beauty devices [1][5][17] Company Overview - GEMO Jinmo is recognized as a leading brand in the Swiss high-end anti-aging home beauty device market, partnering with LaClinic Montreux to enhance its product offerings [5][11] - LaClinic Montreux, founded by Dr. Michel E. Pfulg, is renowned for its personalized anti-aging treatments and is considered a benchmark in the global anti-aging field [11][13] Market Insights - The global anti-aging beauty market surpassed $60 billion in 2022, with a projected annual growth rate of 9.5% until 2030 [7] - In China, the anti-aging beauty device market exceeded 10 billion yuan in 2022, with expectations of over 20% annual growth in the next five years [7] Product Innovation - GEMO Jinmo has developed innovative products such as the GEMO Jinmo Collagen Machine, which integrates advanced technologies for effective cellular anti-aging [8][14] - The collaboration emphasizes a philosophy of "technology + experience + aesthetics," aiming to redefine cellular anti-aging technology in various scenarios [5][10] Strategic Collaboration - The partnership between GEMO Jinmo and LaClinic Montreux aims to create the world's first integrated medical and wellness care space, enhancing the customer experience [5][10] - Dr. Pfulg's visit to GEMO Jinmo's R&D center signifies a deepening of their strategic collaboration, reinforcing their commitment to advancing anti-aging technologies [1][17] Consumer Trends - There is a growing consumer demand for home beauty devices that are non-invasive, safe, and effective, leading to a shift towards high-end, professional-grade products [7][10] - GEMO Jinmo's focus on long-lasting, natural beauty aligns with changing consumer preferences in the anti-aging market [10][13]